A detailed history of Met Life Investment Management, LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 13,721 shares of ARCT stock, worth $219,810. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,721
Previous 13,721 -0.0%
Holding current value
$219,810
Previous $334,000 4.79%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$24.35 - $44.39 $33,943 - $61,879
1,394 Added 11.31%
13,721 $334,000
Q1 2024

May 14, 2024

BUY
$31.23 - $42.99 $384,972 - $529,937
12,327 New
12,327 $416,000
Q2 2023

Apr 29, 2024

BUY
$23.94 - $32.36 $295,108 - $398,901
12,327 New
12,327 $353,000
Q1 2023

May 09, 2024

BUY
$14.72 - $23.97 $181,453 - $295,478
12,327 New
12,327 $295 Million
Q1 2022

May 10, 2024

BUY
$17.64 - $39.57 $217,448 - $487,779
12,327 New
12,327 $332,000
Q1 2022

Mar 22, 2023

BUY
$17.64 - $39.57 $86,700 - $194,486
4,915 Added 66.31%
12,327 $332,000
Q1 2022

May 12, 2022

BUY
$17.64 - $39.57 $86,700 - $194,486
4,915 Added 66.31%
12,327 $332,000
Q4 2021

Jun 21, 2023

SELL
$34.2 - $47.56 $168,093 - $233,757
-4,915 Reduced 39.87%
7,412 $274,000
Q3 2021

May 17, 2024

SELL
$27.88 - $58.25 $42,572 - $88,947
-1,527 Reduced 17.08%
7,412 $354,000
Q3 2021

Jun 21, 2023

SELL
$27.88 - $58.25 $137,030 - $286,298
-4,915 Reduced 39.87%
7,412 $354,000
Q3 2021

Mar 22, 2023

SELL
$27.88 - $58.25 $42,572 - $88,947
-1,527 Reduced 17.08%
7,412 $354,000
Q3 2021

Nov 15, 2021

SELL
$27.88 - $58.25 $42,572 - $88,947
-1,527 Reduced 17.08%
7,412 $354,000
Q2 2021

Jun 21, 2023

SELL
$25.79 - $42.11 $87,376 - $142,668
-3,388 Reduced 27.48%
8,939 $302,000
Q1 2021

May 17, 2024

SELL
$38.75 - $86.92 $131,285 - $294,484
-3,388 Reduced 27.48%
8,939 $369,000
Q1 2021

Jun 26, 2023

SELL
$38.75 - $86.92 $131,285 - $294,484
-3,388 Reduced 27.48%
8,939 $369 Million
Q4 2020

May 24, 2024

BUY
$34.61 - $123.66 $64,201 - $229,389
1,855 Added 26.19%
8,939 $387,000
Q4 2020

Jun 22, 2023

SELL
$34.61 - $123.66 $117,258 - $418,960
-3,388 Reduced 27.48%
8,939 $387,000
Q4 2020

Mar 22, 2023

BUY
$34.61 - $123.66 $64,201 - $229,389
1,855 Added 26.19%
8,939 $387,000
Q4 2020

Feb 16, 2021

BUY
$34.61 - $123.66 $64,201 - $229,389
1,855 Added 26.19%
8,939 $388,000
Q3 2020

May 24, 2024

BUY
$37.49 - $63.19 $38,989 - $65,717
1,040 Added 17.21%
7,084 $304 Million
Q3 2020

Jun 26, 2023

SELL
$37.49 - $63.19 $196,560 - $331,305
-5,243 Reduced 42.53%
7,084 $303,000
Q3 2020

Mar 22, 2023

BUY
$37.49 - $63.19 $38,989 - $65,717
1,040 Added 17.21%
7,084 $303,000
Q3 2020

Nov 13, 2020

BUY
$37.49 - $63.19 $38,989 - $65,717
1,040 Added 17.21%
7,084 $304,000
Q2 2020

May 24, 2024

SELL
$12.66 - $58.27 $79,542 - $366,110
-6,283 Reduced 50.97%
6,044 $282 Million
Q2 2020

Jun 26, 2023

SELL
$12.66 - $58.27 $79,542 - $366,110
-6,283 Reduced 50.97%
6,044 $282,000
Q2 2020

Mar 22, 2023

SELL
$12.66 - $58.27 $79,542 - $366,110
-6,283 Reduced 50.97%
6,044 $282,000
Q2 2020

Aug 14, 2020

BUY
$12.66 - $58.27 $76,517 - $352,183
6,044 New
6,044 $282,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $426M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.